Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19768959 | 0.84 | EGFR (0.34) | MAPK1SMN1; SMN2EGFRERBB2PTPN1 | |
| SCHEMBL20621285 | 0.81 | L3MBTL1 (0.38) | MAPK1SMN1; SMN2EGFRERBB2PTPN1 | |
| SCHEMBL19780122 | 0.78 | TSHR (0.32) | MAPK1SMN1; SMN2EGFRERBB2PTPN1 | |
| SCHEMBL23269915 | 0.73 | PTPN1 (0.49) | EGFRERBB2PTPN1GAAXDH | |
| SCHEMBL22096809 | 0.73 | SSTR2 (0.38) | MAPK1SMN1; SMN2EGFRERBB2GAA | |
| SCHEMBL21883705 | 0.73 | TDP1 (0.34) | SMN1; SMN2EGFRERBB2PTPN1GAA | |
| SCHEMBL21883592 | 0.72 | CYP1A2 (0.34) | — | |
| SCHEMBL21883586 | 0.72 | TSHR (0.38) | MAPK1SMN1; SMN2 | |
| SCHEMBL21143326 | 0.72 | EGFR (0.39) | EGFRERBB2PTPN1GAAXDH | |
| SCHEMBL30509819 | 0.72 | EGFR (0.39) | EGFRERBB2PTPN1GAAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | MAPK1 2655/4885SMN1; SMN2 1197/4885EGFR 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.